Ocular Therapeutix, Inc. (OCUL) vs uniQure N.V. (QURE)
A side-by-side comparison of Ocular Therapeutix, Inc. and uniQure N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OCUL
Ocular Therapeutix, Inc.
$7.32HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
QURE
uniQure N.V.
$23.27HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Total return — OCUL vs QURE
growth of $100 · dividends reinvested · last 10yOCUL +5.8% (+0.6%/yr)QURE +188.2% (+11.2%/yr)QURE compounded faster over this window
OCUL QURE
OCUL vs QURE: by the numbers
- •QURE is the larger company ($1.61B vs $1.60B market cap).
- •Both run net losses; OCUL's is the smaller (-579.10% vs -1350.73% net margin).
- •OCUL grew revenue faster over the past five years (10.03% vs -48.20% CAGR).
Metrics side by side
Valuation
| Metric | OCUL | QURE |
|---|---|---|
| P/S ratio | 30.77 | 86.46 |
| P/B ratio | 3.08 | 4.98 |
Profitability
| Metric | OCUL | QURE |
|---|---|---|
| Gross margin | 87.11% | 89.53% |
| Operating margin | -521.04% | -1166.77% |
| Net margin | -579.10% | -1350.73% |
| ROE | -57.97% | -77.83% |
| ROIC | -50.20% | -22.55% |
Growth (annualized)
| Metric | OCUL | QURE |
|---|---|---|
| Revenue CAGR (5Y) | 10.03% | -48.20% |
| Total return CAGR (5Y) | -5.73% | -6.16% |
Frequently asked
- Which has grown faster, OCUL or QURE?
- Over the past five years, OCUL grew revenue faster — OCUL at a 10.03% CAGR versus QURE at -48.20%.
- How have OCUL and QURE total returns compared?
- Over the past 10 years, OCUL delivered 0.44% and QURE delivered 11.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.